Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Spesolimab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 27 Feb 2023 Primary endpoint has not been met, (Percentage change from baseline in the Eczema Area and Severity Index (EASI) Score at Week 16), as per Results published in the Journal of the European Academy of Dermatology and Venereology
- 27 Feb 2023 Results published in the Journal of the European Academy of Dermatology and Venereology
- 16 Sep 2020 Status changed from active, no longer recruiting to completed.